Response to Zhang and Fang
- PMID: 40531502
- DOI: 10.14309/ajg.0000000000003566
Response to Zhang and Fang
References
-
- Yan Zhang Y, Fang Y. Optimizing fibrosis screening in T2DM: Key limitations and future directions. Am J Gastroenterol 2025, this issue.
-
- Caviglia GP, Ferro A, D'Ambrosio R, et al. Effectiveness of a model of care based on fibrosis-4 and liver stiffness measurement for the screening of patients with type 2 diabetes mellitus at risk of advanced liver disease: Results from an Italian Prospective Multicenter Study. Am J Gastroenterol 2025, this issue. doi. 10.14309/ajg.0000000000003493 - DOI
-
- Wang H, Ye J, Chen Y, et al. High sensitivity C-reactive protein implicates heterogeneous metabolic phenotypes and severity in metabolic dysfunction associated-steatotic liver disease. BMC Gastroenterol 2025;25(1):231.
-
- Armandi A, Rosso C, Caviglia GP, et al. An updated overview on hepatocellular carcinoma in patients with Metabolic dysfunction-associated steatotic liver disease: Trends, pathophysiology and risk-based surveillance. Metabolism 2025;162:156080.
-
- Younes R, Govaere O, Petta S, et al. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: Time for reappraisal of BMI-driven approach? Gut 2022;71(2):382–90.
LinkOut - more resources
Full Text Sources